Search

Your search keyword '"Munshi, Nikhil C"' showing total 3,545 results
Start Over Author "Munshi, Nikhil C"
3,545 results on '"Munshi, Nikhil C"'

4. Author Correction: The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells

Author

Zhu, Di, Wang, Zhongqiu, Zhao, Jian-Jun, Calimeri, Teresa, Meng, Jiang, Hideshima, Teru, Fulciniti, Mariateresa, Kang, Yue, Ficarro, Scott B., Tai, Yu-Tzu, Hunter, Zachary, McMilin, Douglas, Tong, Haoxuan, Mitsiades, Constantine S., Wu, Catherine J., Treon, Steven P., Dorfman, David M., Pinkus, Geraldine, Munshi, Nikhil C., Tassone, Pierfrancesco, Marto, Jarrod A., Anderson, Kenneth C., and Carrasco, Ruben D.

Published
2024
Full Text
View/download PDF

7. Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies

Author

Deng, Shuhui, Derebail, Sanika, Weiler, Vera Joy, Fong Ng, Jessica, Maroto-Martin, Elena, Chatterjee, Madhumouli, Giorgetti, Giulia, Chakraborty, Chandraditya, Kalhotra, Poonam, Du, Ting, Yao, Yao, Prabhala, Rao, Shammas, Masood, Gulla, Annamaria, Aktas Samur, Anil, Samur, Mehmet Kemal, Qiu, Lugui, Anderson, Kenneth C., Fulciniti, Mariateresa, and Munshi, Nikhil C.

Published
2024
Full Text
View/download PDF

8. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial

Author

Lin, Yi, Raje, Noopur S., Berdeja, Jesús G., Siegel, David S., Jagannath, Sundar, Madduri, Deepu, Liedtke, Michaela, Rosenblatt, Jacalyn, Maus, Marcela V., Massaro, Monica, Petrocca, Fabio, Yeri, Ashish, Finney, Olivia, Caia, Andrea, Yang, Zhihong, Martin, Nathan, Campbell, Timothy B., Rytlewski, Julie, Fuller, Jaymes, Hege, Kristen, Munshi, Nikhil C., and Kochenderfer, James N.

Published
2023
Full Text
View/download PDF

9. Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

Author

Gulla, Annamaria, Morelli, Eugenio, Johnstone, Megan, Turi, Marcello, Samur, Mehmet K., Botta, Cirino, Cifric, Selma, Folino, Pietro, Vinaixa, Delaney, Barello, Francesca, Clericuzio, Cole, Favasuli, Vanessa Katia, Maisano, Domenico, Talluri, Srikanth, Prabhala, Rao, Bianchi, Giada, Fulciniti, Mariateresa, Wen, Kenneth, Kurata, Keiji, Liu, Jiye, Penailillo, Johany, Bragoni, Alberto, Sapino, Anna, Richardson, Paul G., Chauhan, Dharminder, Carrasco, Ruben D., Hideshima, Teru, Munshi, Nikhil C., and Anderson, Kenneth C.

Published
2024
Full Text
View/download PDF

10. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma

Author

Delforge, Michel, Shah, Nina, San F. Miguel, Jesús, Braverman, Julia, Dhanda, Devender S, Shi, Ling, Guo, Shien, Yu, Peiwen, Liao, Weiqin, Campbell, Timothy B, and Munshi, Nikhil C

Subjects
Chronic Pain, Hematology, Pain Research, Behavioral and Social Science, Rare Diseases, Clinical Trials and Supportive Activities, Health Services, Cancer, Clinical Research, Fatigue, Humans, Multiple Myeloma, Pain, Quality of Life, Receptors, Chimeric Antigen
Abstract

Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, showed deep, durable responses in patients with triple-class exposed, relapsed and refractory multiple myeloma (RRMM) in the phase 2 KarMMa (Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma) trial. We assessed health-related quality of life (HRQoL) among KarMMa patients. The European Organization for Research and Treatment of Cancer Quality of Life C30 Questionnaire and its supplementary 20-item multiple myeloma module, as well as the EuroQol 5-dimension 5-level instrument, were administered at screening, baseline (≤72 hours before or same day as lymphodepletion), day of ide-cel treatment, and after ide-cel treatment. Mean changes from baseline that exceeded the predetermined threshold of minimally important difference were deemed clinically meaningful. The proportions of patients experiencing clinically meaningful changes in HRQoL were assessed using within-patient change thresholds. Time to stable improvement (≥2 consecutive visits with clinically meaningful HRQoL improvements) was analyzed by using the Kaplan-Meier method. A total of 126 (98%) of 128 patients treated with ide-cel were included in the HRQoL analysis. Pretreatment baseline RRMM burden was high and meaningfully worse than that in the age- and sex-weighted general population. Statistically significant and clinically meaningful improvements from baseline were observed by month 1 for pain (-8.9) and disease symptoms (-10.2), and by month 2 for fatigue (-7.2), physical functioning (6.1), cognitive functioning (6.7), and global health status/QoL (8.0). Clinically meaningful improvements in fatigue, pain, and physical functioning were most prominent at months 9, 12, and 18, respectively, and were sustained through 15 to 18 months after ide-cel treatment. For triple-class exposed patients with RRMM with a poor prognosis and few treatment options, a single ide-cel infusion provides early, sustained, statistically significant, and clinically meaningful improvements in HRQoL. This study was registered at Clinicaltrials.gov as #NCT03361748.

Published
2022

16. Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal Adenocarcinoma

Author

Kumar, Subodh, Zhao, Jiangning, Talluri, Srikanth, Buon, Leutz, Mu, Shidai, Potluri, Lakshmi B., Liao, Chengcheng, Shi, Jialan, Chakraborty, Chandraditya, Gonzalez, Gabriel B., Tai, Yu-Tzu, Patel, Jaymin, Pal, Jagannath, Mashimo, Hiroshi, Samur, Mehmet K., Munshi, Nikhil C., and Shammas, Masood A.

Published
2023
Full Text
View/download PDF

18. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

Author

Shah, Nina, Aiello, Jack, Avigan, David E, Berdeja, Jesus G, Borrello, Ivan M, Chari, Ajai, Cohen, Adam D, Ganapathi, Karthik, Gray, Lissa, Green, Damian, Krishnan, Amrita, Lin, Yi, Manasanch, Elisabet, Munshi, Nikhil C, Nooka, Ajay K, Rapoport, Aaron P, Smith, Eric L, Vij, Ravi, and Dhodapkar, Madhav

Subjects
Hematology, Immunization, Rare Diseases, Vaccine Related, Biotechnology, Cancer, Orphan Drug, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Consensus, Humans, Immunotherapy, Multiple Myeloma, guidelines as topic, immunotherapy, hematological neoplasms, receptors, chimeric antigen, antineoplastic protocols, receptors, chimeric antigen
Abstract

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor CAR T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.

Published
2020

19. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Author

Yao, Yao, Ng, Jessica Fong, Park, Woojun Daniel, Samur, Mehmet, Morelli, Eugenio, Encinas Mayoral, Jessica, Chyra, Zuzana, Xu, Yan, Derebail, Sanika, Epstein, Charles, Nabet, Behnam, Chesi, Marta, Gray, Nathanael S., Young, Richard A., Kwiatkowski, Nicholas, Mitsiades, Constantine, Anderson, Kenneth C., Lin, Charles Y., Munshi, Nikhil C., and Fulciniti, Mariateresa

Published
2023
Full Text
View/download PDF

21. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Author

Samur, Mehmet Kemal, Roncador, Marco, Aktas Samur, Anil, Fulciniti, Mariateresa, Bazarbachi, Abdul Hamid, Szalat, Raphael, Shammas, Masood A., Sperling, Adam S., Richardson, Paul G., Magrangeas, Florence, Minvielle, Stephane, Perrot, Aurore, Corre, Jill, Moreau, Philippe, Thakurta, Anjan, Parmigiani, Giovanni, Anderson, Kenneth C., Avet-Loiseau, Hervé, and Munshi, Nikhil C.

Published
2023
Full Text
View/download PDF

23. A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

Author

Morelli, Eugenio, Fulciniti, Mariateresa, Samur, Mehmet K., Ribeiro, Caroline F., Wert-Lamas, Leon, Henninger, Jon E., Gullà, Annamaria, Aktas-Samur, Anil, Todoerti, Katia, Talluri, Srikanth, Park, Woojun D., Federico, Cinzia, Scionti, Francesca, Amodio, Nicola, Bianchi, Giada, Johnstone, Megan, Liu, Na, Gramegna, Doriana, Maisano, Domenico, Russo, Nicola A., Lin, Charles, Tai, Yu-Tzu, Neri, Antonino, Chauhan, Dharminder, Hideshima, Teru, Shammas, Masood A., Tassone, Pierfrancesco, Gryaznov, Sergei, Young, Richard A., Anderson, Kenneth C., Novina, Carl D., Loda, Massimo, and Munshi, Nikhil C.

Published
2023
Full Text
View/download PDF

26. Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma

Author

O'Donnell, Elizabeth K., Shapiro, Yael N., Yee, Andrew J., Nadeem, Omar, Laubach, Jacob P., Branagan, Andrew R., Anderson, Kenneth C., Mo, Clifton C., Munshi, Nikhil C., Ghobrial, Irene M., Sperling, Adam S., Agyemang, Emerentia A., Burke, Jill N., Harrington, Cynthia C., Hu, Bonnie Y., Richardson, Paul G., Raje, Noopur S., and El-Jawahri, Areej

Published
2022
Full Text
View/download PDF

28. Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma

Author

Waldschmidt, Johannes M., Yee, Andrew J., Vijaykumar, Tushara, Pinto, Ricardo A., Frede, Julia, Anand, Praveen, Bianchi, Giada, Guo, Guangwu, Potdar, Sayalee, Seifer, Charles, Nair, Monica S., Kokkalis, Antonis, Kloeber, Jake A., Shapiro, Samantha, Budano, Lillian, Mann, Mason, Friedman, Robb, Lipe, Brea, Campagnaro, Erica, O’Donnell, Elizabeth K., Zhang, Cheng-Zhong, Laubach, Jacob P., Munshi, Nikhil C., Richardson, Paul G., Anderson, Kenneth C., Raje, Noopur S., Knoechel, Birgit, and Lohr, Jens G.

Published
2022
Full Text
View/download PDF

29. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

Author

Raje, Noopur S, Anaissie, Elias, Kumar, Shaji K, Lonial, Sagar, Martin, Thomas, Gertz, Morie A, Krishnan, Amrita, Hari, Parameswaran, Ludwig, Heinz, O'Donnell, Elizabeth, Yee, Andrew, Kaufman, Jonathan L, Cohen, Adam D, Garderet, Laurent, Wechalekar, Ashutosh F, Terpos, Evangelos, Khatry, Navin, Niesvizky, Ruben, Yi, Qing, Joshua, Douglas E, Saikia, Tapan, Leung, Nelson, Engelhardt, Monika, Mothy, Mohamad, Branagan, Andrew, Chari, Ajai, Reiman, Anthony J, Lipe, Brea, Richter, Joshua, Rajkumar, S Vincent, Miguel, Jesús San, Anderson, Kenneth C, Stadtmauer, Edward A, Prabhala, Rao H, McCarthy, Phillip L, and Munshi, Nikhil C

Published
2022
Full Text
View/download PDF

30. Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH

Author

Yan, Yuting, Qin, Xiaoqi, Liu, Jiahui, Fan, Huishou, Yan, Wenqiang, Liu, Lanting, Du, Chenxing, Yu, Zhen, Xu, Yan, Hao, Mu, Deng, Shuhui, Sui, Weiwei, Lyu, Rui, Liu, Wei, Wang, Qi, Zou, Dehui, Hu, Linping, Wang, Jianxiang, Tai, Yu-Tzu, Anderson, Kenneth C., Zhang, Lei, Cheng, Tao, Zetterberg, Anders, Munshi, Nikhil C., Qiu, Lugui, and An, Gang

Published
2022
Full Text
View/download PDF

32. Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia

Author

Morelli, Eugenio, Hunter, Zachary R., Fulciniti, Mariateresa, Gullà, Annamaria, Perrotta, Ida Daniela, Zuccalà, Valeria, Federico, Cinzia, Juli, Giada, Manzoni, Martina, Ronchetti, Domenica, Romeo, Enrica, Gallo Cantafio, Maria Eugenia, Soncini, Debora, Maltese, Lorenza, Rossi, Marco, Roccaro, Aldo M., Cea, Michele, Tassone, Pierfrancesco, Neri, Antonino, Treon, Steven C., Munshi, Nikhil C., Viglietto, Giuseppe, and Amodio, Nicola

Published
2022
Full Text
View/download PDF

34. Potentially inappropriate medications and their association with frailty, unplanned hospitalizations, and mortality in patients with cancer treated in the national U.S. Veterans Affairs Healthcare System.

Author

La, Jennifer, primary, Hshieh, Tammy, additional, Hamparsumian, Anahid, additional, Zwolinski, Robert, additional, Wood, Jameson, additional, Dharne, Mayuri, additional, Gaziano, J. Michael, additional, Brophy, Mary T., additional, Do, Nhan, additional, Munshi, Nikhil C., additional, Driver, Jane A., additional, Abel, Gregory A., additional, Fillmore, Nathanael, additional, and DuMontier, Clark, additional

Published
2024
Full Text
View/download PDF

36. Data from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis

Author

Saygin, Caner, primary, Zhang, Pu, primary, Stauber, Jacob, primary, Aldoss, Ibrahim, primary, Sperling, Adam S., primary, Weeks, Lachelle D., primary, Luskin, Marlise R., primary, Knepper, Todd C., primary, Wanjari, Pankhuri, primary, Wang, Peng, primary, Lager, Angela M., primary, Fitzpatrick, Carrie, primary, Segal, Jeremy P., primary, Gharghabi, Mehdi, primary, Gurbuxani, Sandeep, primary, Venkataraman, Girish, primary, Cheng, Jason X., primary, Eisfelder, Bart J., primary, Bohorquez, Oliver, primary, Patel, Anand A., primary, Umesh Nagalakshmi, Sheethal, primary, Jayaram, Savita, primary, Odenike, Olatoyosi M., primary, Larson, Richard A., primary, Godley, Lucy A., primary, Arber, Daniel A., primary, Gibson, Christopher J., primary, Munshi, Nikhil C., primary, Marcucci, Guido, primary, Ebert, Benjamin L., primary, Greally, John M., primary, Steidl, Ulrich, primary, Lapalombella, Rosa, primary, Shah, Bijal D., primary, and Stock, Wendy, primary

Published
2024
Full Text
View/download PDF

37. Supplementary Figures 1-19 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis

Author

Saygin, Caner, primary, Zhang, Pu, primary, Stauber, Jacob, primary, Aldoss, Ibrahim, primary, Sperling, Adam S., primary, Weeks, Lachelle D., primary, Luskin, Marlise R., primary, Knepper, Todd C., primary, Wanjari, Pankhuri, primary, Wang, Peng, primary, Lager, Angela M., primary, Fitzpatrick, Carrie, primary, Segal, Jeremy P., primary, Gharghabi, Mehdi, primary, Gurbuxani, Sandeep, primary, Venkataraman, Girish, primary, Cheng, Jason X., primary, Eisfelder, Bart J., primary, Bohorquez, Oliver, primary, Patel, Anand A., primary, Umesh Nagalakshmi, Sheethal, primary, Jayaram, Savita, primary, Odenike, Olatoyosi M., primary, Larson, Richard A., primary, Godley, Lucy A., primary, Arber, Daniel A., primary, Gibson, Christopher J., primary, Munshi, Nikhil C., primary, Marcucci, Guido, primary, Ebert, Benjamin L., primary, Greally, John M., primary, Steidl, Ulrich, primary, Lapalombella, Rosa, primary, Shah, Bijal D., primary, and Stock, Wendy, primary

Published
2024
Full Text
View/download PDF

38. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study

Author

Kelly, Kevin R, Ailawadhi, Sikander, Siegel, David S, Heffner, Leonard T, Somlo, George, Jagannath, Sundar, Zimmerman, Todd M, Munshi, Nikhil C, Madan, Sumit, Chanan-Khan, Asher, Lonial, Sagar, Chandwani, Suraj, Minasyan, Ashot, Ruehle, Markus, Barmaki-Rad, Farima, Abdolzade-Bavil, Afsaneh, Rharbaoui, Faiza, Herrmann-Keiner, Eva, Haeder, Thomas, Wartenberg-Demand, Andrea, and Anderson, Kenneth C

Published
2021
Full Text
View/download PDF

41. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Author

Berdeja, Jesus G, Madduri, Deepu, Usmani, Saad Z, Jakubowiak, Andrzej, Agha, Mounzer, Cohen, Adam D, Stewart, A Keith, Hari, Parameswaran, Htut, Myo, Lesokhin, Alexander, Deol, Abhinav, Munshi, Nikhil C, O'Donnell, Elizabeth, Avigan, David, Singh, Indrajeet, Zudaire, Enrique, Yeh, Tzu-Min, Allred, Alicia J, Olyslager, Yunsi, Banerjee, Arnob, Jackson, Carolyn C, Goldberg, Jenna D, Schecter, Jordan M, Deraedt, William, Zhuang, Sen Hong, Infante, Jeffrey, Geng, Dong, Wu, Xiaoling, Carrasco-Alfonso, Marlene J, Akram, Muhammad, Hossain, Farah, Rizvi, Syed, Fan, Frank, Lin, Yi, Martin, Thomas, and Jagannath, Sundar

Published
2021
Full Text
View/download PDF

42. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Author

Moreau, Philippe, Kumar, Shaji K, San Miguel, Jesús, Davies, Faith, Zamagni, Elena, Bahlis, Nizar, Ludwig, Heinz, Mikhael, Joseph, Terpos, Evangelos, Schjesvold, Fredrik, Martin, Thomas, Yong, Kwee, Durie, Brian G M, Facon, Thierry, Jurczyszyn, Artur, Sidana, Surbhi, Raje, Noopur, van de Donk, Niels, Lonial, Sagar, Cavo, Michele, Kristinsson, Sigurdur Y, Lentzsch, Suzanne, Hajek, Roman, Anderson, Kenneth C, João, Cristina, Einsele, Hermann, Sonneveld, Pieter, Engelhardt, Monika, Fonseca, Rafael, Vangsted, Annette, Weisel, Katja, Baz, Rachid, Hungria, Vania, Berdeja, Jesus G, Leal da Costa, Fernando, Maiolino, Angelo, Waage, Anders, Vesole, David H, Ocio, Enrique M, Quach, Hang, Driessen, Christoph, Bladé, Joan, Leleu, Xavier, Riva, Eloisa, Bergsagel, Peter Leif, Hou, Jian, Chng, Wee Joo, Mellqvist, Ulf-Henrik, Dytfeld, Dominik, Harousseau, Jean-Luc, Goldschmidt, Hartmut, Laubach, Jacob, Munshi, Nikhil C, Gay, Francesca, Beksac, Meral, Costa, Luciano J, Kaiser, Martin, Hari, Parameswaran, Boccadoro, Mario, Usmani, Saad Z, Zweegman, Sonja, Holstein, Sarah, Sezer, Orhan, Harrison, Simon, Nahi, Hareth, Cook, Gordon, Mateos, Maria-Victoria, Rajkumar, S Vincent, Dimopoulos, Meletios A, and Richardson, Paul G

Published
2021
Full Text
View/download PDF

44. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia

Author

Li, Na, Lopez, Michael A., Linares Gómez, María, Kumar, Subodh, Oliva, Stefania, Martinez-Lopez, Joaquin, Xu, Lian, Xu, Yan, Perini, Tommaso, Senapedis, William, Baloglu, Erkan, Shammas, Masood A., Hunter, Zachary, Anderson, Kenneth C., Treon, Steven P., Munshi, Nikhil C., Fulciniti, Mariateresa, Li, Na, Lopez, Michael A., Linares Gómez, María, Kumar, Subodh, Oliva, Stefania, Martinez-Lopez, Joaquin, Xu, Lian, Xu, Yan, Perini, Tommaso, Senapedis, William, Baloglu, Erkan, Shammas, Masood A., Hunter, Zachary, Anderson, Kenneth C., Treon, Steven P., Munshi, Nikhil C., and Fulciniti, Mariateresa

Abstract

Purpose: p21-activated kinase 4 (PAK4) plays a significant biological and functional role in a number of malignancies, including multiple myeloma (MM). On the basis of our promising findings in MM, we here characterize PAK4 expression and role in WM cells, as well effect of dual PAK4-NAMPT inhibitor (KPT-9274) against WM cell growth and viability. Experimental Design: We have analyzed mRNA and protein expression levels of PAK4 in WM cells, and used loss-offunction approach to investigate its contribution to WM cell viability. We have further tested the in vitro and in vivo effect of KPT-9274 against WM cell growth and viability. Results: We report here high-level expression and functional role of PAK4 in WM, as demonstrated by shRNA-mediated knockdown; and significant impact of KPT-9274 on WM cell growth and viability. The growth inhibitory effect of KPT-9274 was associated with decreased PAK4 expression and NAMPT activity, as well as induction of apoptosis. Interestingly, in WM cell lines treated with KPT-9274, we detected a significant impact on DNA damage and repair genes. Moreover, we observed that apart from inducing DNA damage, KPT-9274 specifically decreased RAD51 and the double-strand break repair by the homologous recombination pathway. As a result, when combined with a DNA alkylating agents bendamustine and melphalan, KPT-9274 provided a synergistic inhibition of cell viability in WM cell lines and primary patient WM cells in vitro and in vivo. Conclusions: These results support the clinical investigation of KPT-9274 in combination with DNA-damaging agent for treatment of WM., NIH, Department of Veterans Affairs Merit Review Award, Depto. de Bioquímica y Biología Molecular, Fac. de Farmacia, TRUE, pub

Published
2024

45. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Author

Chari, Ajai, Samur, Mehmet Kemal, Martinez-Lopez, Joaquin, Cook, Gordon, Biran, Noa, Yong, Kwee, Hungria, Vania, Engelhardt, Monika, Gay, Francesca, García Feria, Ana, Oliva, Stefania, Oostvogels, Rimke, Gozzetti, Alessandro, Rosenbaum, Cara, Kumar, Shaji, Stadtmauer, Edward A., Einsele, Hermann, Beksac, Meral, Weisel, Katja, Anderson, Kenneth C., Mateos, María-Victoria, Moreau, Philippe, San-Miguel, Jesus, Munshi, Nikhil C., and Avet-Loiseau, Hervé

Published
2020
Full Text
View/download PDF

48. Retraction: Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of β1-Integrin and Phosphatidylinositol 3′-Kinase/AKT Signaling

Author

Tai, Yu-Tzu, primary, Podar, Klaus, additional, Catley, Laurence, additional, Tseng, Yu-Hua, additional, Akiyama, Masaharu, additional, Shringarpure, Reshma, additional, Burger, Renate, additional, Hideshima, Teru, additional, Chauhan, Dharminder, additional, Mitsiades, Nicholas, additional, Richardson, Paul, additional, Munshi, Nikhil C., additional, Kahn, C. Ronald, additional, Mitsiades, Constantine, additional, and Anderson, Kenneth C., additional

Published
2024
Full Text
View/download PDF

49. Retraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications

Author

Tai, Yu-Tzu, primary, Catley, Laurence P., additional, Mitsiades, Constantine S., additional, Burger, Renate, additional, Podar, Klaus, additional, Shringpaure, Reshma, additional, Hideshima, Teru, additional, Chauhan, Dharminder, additional, Hamasaki, Makoto, additional, Ishitsuka, Kenji, additional, Richardson, Paul, additional, Treon, Steven P., additional, Munshi, Nikhil C., additional, and Anderson, Kenneth C., additional

Published
2024
Full Text
View/download PDF

50. Retraction: Nuclear Factor-κB p65 Mediates Tumor Necrosis Factor α-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein

Author

Akiyama, Masaharu, primary, Hideshima, Teru, additional, Hayashi, Toshiaki, additional, Tai, Yu-Tzu, additional, Mitsiades, Constantine S., additional, Mitsiades, Nicholas, additional, Chauhan, Dharminder, additional, Richardson, Paul, additional, Munshi, Nikhil C., additional, and Anderson, Kenneth C., additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results